Immunomodulatory Clarithromycin Treatment of Experimental Sepsis and Acute Pyelonephritis Caused by Multidrug-Resistant Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 1, 2004, Pages 93-99

  Giamarellos Bourboulis, Evangelos J ^a,d   Adamis, Theodoros ^b   Laoutaris, George ^a   Sabracos, Lambros ^b   Koussoulas, Vassilios ^a   Mouktaroudi, Maria ^a   Perrea, Despina ^b   Karayannacos, Panayotis E ^c   Giamarellou, Helen ^a  

^a 4th Department of Internal Medicine   (Greece)

^b Laboratory of Experimental Surgery   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CLARITHROMYCIN; ENDOTOXIN; MALONALDEHYDE; THIOBARBITURIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PYELONEPHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL; BACTERIAL COUNT; BIOASSAY; BLOOD LEVEL; BODY WEIGHT; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; EXPERIMENTAL MODEL; FOLLOW UP; IMMUNOMODULATION; INJECTION; KIDNEY INFECTION; KIDNEY PELVIS; LIMULUS LYSATE TEST; LIVER; LUNG; LYMPH NODE; MALE; MEASUREMENT; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; PSEUDOMONAS AERUGINOSA; RABBIT; SAMPLE; SAMPLING; SEPSIS; SPLEEN; SURVIVAL TIME; TIME; TISSUE; URETER LIGATION;

ACUTE DISEASE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; IMMUNITY; LIPOPOLYSACCHARIDES; MALE; MALONDIALDEHYDE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PYELONEPHRITIS; RABBITS; SEPSIS; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0347361713     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.1.93-99.2004     Document Type: Article

References (28)

1. Arndt, P., and E. Abraham. 2001. Immunological therapies for sepsis. Intensive Care Med. 27(Suppl. 1):S104-S115.
2. Berry, V., R. Page, J. Satterfield, C. Singley, R. Straub, and G. Woodnut. 2000. Comparative efficacy of gemifloxacin in experimental models of pyelonephritis and wound infection. J. Antimicrob. Chemother. 45(Suppl. 1): 87-93.
3. But, K. Q., M. A. Banevicius, C. H. Nightingale, R. Quintiliani, and D. P. Nicolau. 2000. In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa. J. Antimicrob. Chemother. 45:57-62.
4. Chapin-Robinson, K., and S. C. Edberg. 1991. Measurement of antibiotics in human body fluids: techniques and significance, p. 295-366. In V. Lorian (ed.), Antibiotics in laboratory medicine, 2nd ed. The Williams & Wilkins Co., Baltimore, Md.
5. Culic, O., V. Erakovic, and M. J. Parnham. 2001. Anti-inflammatory effects of macrolide antibiotics. Eur. J. Pharmacol. 429:209-229.
6. Engelhard, D., S. Pomernz, S. Gallily, N. Strauss, and E. Tuomanen. 1997. Serotype-related differences in inflammatory response to Streptococcus pneumoniae in experimental meningitis. J. Infect. Dis. 175:979-982.
7. Frendéus, B., G. Godaly, L. Hang, D. Karpman, A. C. Lundstedt, and C. Svanborg. 2000. Interleukin 8 receptor deficiency confers susceptibility to acute experimental pyelonephritis and may have a human counterpart. J. Exp. Med. 192:881-890.
8. Giamarellos-Bourboulis, E. J., P. Grecka, A. Dionyssiou-Asteriou, and H. Giamarellou. 1998. In vitro activity of polyunsaturated fatty acids on Pseudomonas aeruginosa: relationship to lipid peroxidation. Prostaglandins Leukot. Essent. Fatty Acids 58:283-287.
9. Giamarellos-Bourboulis, E. J., H. Poulaki, N. Kostomitsopoulos, I. Dontas, D. Perrea, P. E. Karayannacos, and H. Giamarellou. 2003. Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide. Antimicrob. Agents Chemother. 47:2445-2449.
10. Goode, H. F., H. C. Cowley, B. E. Walker, P. D. Howdle, and N. R. Webster. 1995. Decreased antioxidant status and increased lipid peroxidation in patients with septic shock and secondary organ dysfunction. Crit. Care Med. 23:646-651.
11. Ianaro, A., A. Ialenti, P. Maffia P. L. Suatebin, L. Rompola, R. Carnuccio, T. Iuvone, F. D'Acquisto, and M. Di Rosa. 2000. Anti-inflammatory activity of macrolide antibiotics. J. Pharmacol. Exp. Toxicol. 292:156-163.
12. Kawamura-Sato, K., Y. Iinuma, T. Hasegawa, T. Horii, T. Yamashino, and M. Ohta. 2000. Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob. Agents Chemother. 44:2869-2872.
13. Khalil, A., K. Tullus, T. Bartfai, M. Bakhiet, G. Jaremko, and A. Brauner. 2000. Renal cytokine responses in acute Escherichia coli pyelonephritis in IL-6-deficient mice. Clin. Exp. Immunol. 122:200-206.
14. Kikuchi, T., K. Hagiwara, Y. Honda, Y., K. Gomi, T. Kobayashi, H. Takahashi, Y. Tokue, A. Watanabe, and T. Nukiwa. 2002. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J. Antimicrob. Chemother. 49:745-755.
15. Kobayashi, T., K. Tatade, T. Matsumoto, S. Miyazaki, A. Watanabe, T. Nukiwa, and K. Yamaguchi. 2002. Macrolide-treated Pseudomonas aeruginosa induces paradoxical host responses in the lungs of mice and a high mortality rate. J. Antimicrob. Chemother. 50:59-66.
16. Muzio, G., R. A. Salvo, A. Trombetta, R. Autelli, M. Maggiora, M. Terreno, M. U. Dianzani, and R. A. Canuto. 1999. Dose-dependent inhibition of cell proliferation induced by lipid peroxidation products in rat hepatoma cells after enrichment with arachidonic acid. Lipids 34:705-711.
17. Ohtani, H., C. Taninaka, E. Hanada, H. Kotaki, H. Sato, Y. Sawada, and T. Iga. 2000. Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. Antimicrob. Agents Chemother. 44:2630-2637.
18. Rangel Frausto, M. S. 1999. The epidemiology of bacterial sepsis. Infect. Dis. Clin. N. Am. 13:299-311.
19. Robaux, M. A., L. Dube, J. Caillon, D. Bugnon, M. F. Kergueris, D. Navas, P. Le Conte, D. Barron, and G. Patel. 2001. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model. J. Antimicrob. Chemother. 47:617-622.
20. Scaglione, F., and G. Rossoni. 1998. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J. Antimicrob. Chemother. 41(Suppl. B):47-50.
21. Tagaya, E., J. Tamaoki, M. Kondo, and A. Nagai. 2002. Effect of short course of clarithromycin therapy on sputum production in patients with chronic airway obstruction. Chest 122:213-218.
22. Tateda, K., Y. Ishii, T. Matsumoto, T. Kobayashi, S. Miyazaki, and K. Yamagushi. 2000. Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response. J. Infect. Chemother. 6:1-7.
23. Tessier, P. R., M. K. Kim, W. Zhou, D. Xuan, M. Ye, C. H. Nightingale, and D. P. Nicolau. 2002. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob. Agents Chemother. 46:1425-1434.
24. Woo, P. C. Y., L. W. C. Chow, E. S. K. Ma, and K. Y. Yuen. 1999. Clarithromycin attenuates the inflammatory response induced by surgical trauma in a guinea pig model. Pharmacol. Res. 39:49-54.
25. Yamaryo, T., K. Oishi, H. Yoshimine, Y. Tsuchihashi, K. Matsushima, and T. Nagatake. 2003. Fourteen-member macrolide promote the phosphatidylserine receptor-dependent phagocytosis of apoptotic neutrophils by alveolar macrophages. Antimicrob. Agents Chemother. 47:48-53.
26. Yanagihara, K., K. Tomono, M. Kuroki, Y. Kaneko, T. Sawai, H. Ohno, Y. Miyazaki, Y. Higashiyama, S. Maesaki, and J. Kadota. 2000. Intrapulmonary concentrations of inflammatory cytokines in a mouse model of chronic respiratory infection caused by Pseudomonas aeruginosa. Clin. Exp. Immunol. 122:67-71.
27. Yanagihara, K., K. Tomono, Y. Imamura, Y. Kaneko, T. Sawai, Y. Miyasaki, Y. Hirakata, H. Mukae, J. Kadota, and S. Kohno. 2002. Effect of clarithromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. J. Antimicrob. Chemother. 49:867-870.
28. Yanagihara, K., K. Tomono, T. Sawai, M. Kuroki, Y. Kaneko, H. Ohno, Y. Higashiyama, Y. Miyazaki, Y. Hirakata, S. Maesaki, J. Kadota, T. Tashiro, and S. Kohno. 2000. Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation. J. Antimicrob. Chemother. 46:69-72.